Loading...
Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era
Target-oriented agents improve metastatic colorectal cancer (mCRC) survival in combination with chemotherapy. However, the majority of patients experience disease progression after first-line treatment and are eligible for second-line approaches. In such a context, antiangiogenic and anti-Epidermal...
Na minha lista:
| Udgivet i: | Int J Mol Sci |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8307359/ https://ncbi.nlm.nih.gov/pubmed/34299337 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms22147717 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|